title: A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer.
abstract: OBJECTIVE
  Cisplatin-gemcitabine (PG) and cisplatin-etoposide (PE) combinations are active regimens for non-small cell lung cancer (NSCLC). The present study aimed to compare PG with PE in the treatment of patients with stage IIIB and IV NSCLC.
  
  
  METHODS
  We conducted a prospective, multicentre trial. A total of 166 patients were enrolled into the study and received either gemcitabine (1,000 mg/m(2)) on days 1, 8 and 15 plus cisplatin (80 mg/m(2)) on day 2 every 4 weeks, or etoposide (100 mg/m(2)) on days 1, 2 and 3 plus cisplatin (80 mg/m(2)) on day 1 every 3 weeks.
  
  
  RESULTS
  The overall response rate was superior in the PG group (54.8%vs 39.0%, P=0.045). There was no significant difference in survival between the two groups, with respective median and 1-year survival of 38 weeks and 33.3% for the PG group, and 34 weeks and 23.2% for the PE group. There was also no statistical difference for time to progression between the two groups. Neutropenia and thrombocytopenia were seen more frequently in the PG group (grade 3 neutropenia, 33.3%vs 15.9%, P=0.012; grade 3 thrombocytopenia, 27.4%vs 3.7%, P<0.001 and grade 4 thrombocytopenia, 10.7%vs 1.2%, P=0.018).
  
  
  CONCLUSIONS
  PG is an active chemotherapy regimen and has a better response rate than PE in advanced NSCLC, although there was no difference in time to progression and overall survival. A higher incidence of haematological toxicity was seen with PG than with PE.
authors.affiliation: Ege University Medical School, Izmir, Turkey. tgoksel@med.ege.edu.tr
authors.forename: Tuncay
authors.initials: T
authors.lastname: Goksel
authors.forename: Osman Nuri
authors.initials: ON
authors.lastname: Hatipoglu
authors.forename: Can
authors.initials: C
authors.lastname: Ozturk
authors.forename: Metin
authors.initials: M
authors.lastname: Gorguner
authors.forename: Murat
authors.initials: M
authors.lastname: Kiyik
authors.forename: Ugur
authors.initials: U
authors.lastname: Yilmaz
authors.forename: Asuman
authors.initials: A
authors.lastname: Guzelant
authors.forename: Sezai
authors.initials: S
authors.lastname: Tasbakan
authors.forename: Erhan
authors.initials: E
authors.lastname: Tabakoglu
authors.forename: Hikmet
authors.initials: H
authors.lastname: Firat
authors.forename: Umit
authors.initials: U
authors.lastname: Tutar
authors.forename: Sadettin
authors.initials: S
authors.lastname: Cikrikicioglu
authors.forename: Atila
authors.initials: A
authors.lastname: Akkoclu
authors.forename: Serdar
authors.initials: S
authors.lastname: Soyer
authors.forename: Ebru
authors.initials: E
authors.lastname: Cakir
authors.forename: Oya
authors.initials: O
authors.lastname: Itil
authors.forename: Salahattin
authors.initials: S
authors.lastname: Sanal
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014421:Turkey; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D005047:Etoposide; D002945:Cisplatin; D000093542:Gemcitabine